Welcome to the ValueWiki BioMarin Pharmaceutical Inc. (BMRN) article! Register for free or click the "edit" link to contribute!

BioMarin Pharmaceutical Inc. (BMRN)

From ValueWiki

Jump to: navigation, search

Launch Chat Window

NASD \ Healthcare \ Biotechnology

BioMarin is a biopharmaceutical company that researches, develops and commercializes drugs that treats serious diseases and medical conditions. Its portfolio of drugs is focused on enzyme replacement class of drugs.

1 Company Analysis
2 Commercialized Products
- 2.1 Aldurazyme
- 2.2 Naglazyme
3 Product Pipeline
- 3.1 Phenoptin
- 3.2 6R-BH4 for Cardiovascular indications
4 News Feed
5 Risks
6 Research Links
7 Options
8 Notes

Today

Max

Funds w/ BMRN:	43
Rank:	309 / 351

[edit]

Company Analysis

[edit]

Commercialized Products

Biomarin has 2 marketted products: Aldurazyme and Naglazyme

[edit]

Aldurazyme

Aldurazyme� (laronidase)is a polymorphic variant of the human enzyme deficient in MPS I, alpha-L-iduronidase. The drug has been approved as a treatment option for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.

The drug is manufactured by Biomarin and marketted by Genzyme (GENZ) with 50-50 sharing of net income. In full year 2005 and 3 quarters of 2006 the drug's revenue was $76.6 million and $69.9 million respectively. ^[1]

It was approved Nov 1, 2007 in Japan for exclusive treatment of MPS I in Japan.

[edit]

Naglazyme

NAGLAZYME (galsulfase) is a normal variant form of the polymorphic human enzyme, N�acetylgalactosamine 4-sulfatase that is produced by recombinant DNA technology in a Chinese hamster ovary cell line. It is approved to treat Mucopolysaccharidosis VI (MPS VI).

Drug revenue:^[1]

2005 Q2: $.1 mm Q3: $2.3 mm Q4: $3.7 mm

2006 Q1: $ 7 mm Q2: $10.3 mm Q3: $12.9 mm

More about MPS from Wikipedia

[edit]

Product Pipeline

[edit]

Phenoptin

BioMarin has rights for US, Serono holds the rights outside US.

Small molecule ynthetic form of 6R-BH4 (tetrahydrobiopterin),
In March 2006 announced that endpoints were met and in January 2007, more positive data in trials involving children were announced and the company said the drug is on schedule to get approved in 2Q 2007. ^[2]

[edit]

6R-BH4 for Cardiovascular indications

Phase 2 clinical study in poorly controlled hypertension under way; on track to announce data in Q107
Phase 2 clinical study in peripheral arterial disease targeted to begin in late Q406
6R-BH4 is the same enzyme cofactor currently in Phase 3 development for the treatment of PKU

[edit]

News Feed

11/28/08 12:11 pm	Stocks to Avoid Now? (at Motley Fool)
11/25/08 9:11 am	BioMarin to Present at the Piper Jaffray Healthcare Conference (PR Newswire)
11/24/08 12:11 pm	BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (EDGAR Online)
11/23/08 10:11 am	New Emerging Biotech and Pharma Company Index (at Seeking Alpha)
11/21/08 7:11 pm	BioMarin shares rise on Citi upgrade to 'Buy' (AP)
11/21/08 4:11 pm	BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer (PR Newswire)
11/21/08 2:11 pm	Movers roundup: JPMorgan Chase, Foot Locker (AP)
11/21/08 8:11 am	Analysts' Upgrades, Downgrades: Microsoft (at TheStreet.com)
11/21/08 5:11 am	Biomarin Pharm upgraded by Citigroup (Briefing.com)
11/19/08 9:11 am	Outlook for Small Cap Biotechnology Companies Discussed in Wall Street Transcript Report (Wall Street Transcript)